drugset / Trial / NCT00004022

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

NCT00004022

Treatment

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery in treating patients who have stage III or stage IV melanoma.

Timeline

Start
1997-06
Primary completion
2004-01
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Intravenous
Subject autologous tumor cell vaccine Vaccine
Subject therapeutic autologous lymphocytes Cell therapy Intravenous
Background muromonab-CD3 Monoclonal antibody

Indications